Jurata logo

Jurata

Addressing biologicals cold chain dependence while enabling mucosal administration.

UT Seed Fund Portco
HQ Region Durham, NC

Jurata has developed a formulation platform that thermostabilizes a wide range of biologics for ambient storage, eliminating the dependency for cold-chain infrastructure. The platform also enables mucosal administration (such as oral, sublingual, or intranasal) via liquid or self-administered solid film presentations.

Jurata's process can be readily integrated into manufacturing with no change in the drug substance process or need for administration devices and no need for lyophilization. Jurata's team brings significant business and formulation development experience.

Founded 2019
UT Seed Fund Nov 2022
Status Active
Careers page Careers page
Founders
Tim Obara | CEO | Tim Obara is a seasoned biopharmaceutical executive with over 30 years of global experience spanning vaccines, oncology, and cell and gene therapy. He has held leadership roles across commercial, manufacturing, business development, and R&D strategy at companies including Merck, GSK, AstraZeneca, Amicus Therapeutics, and Genenta Science. Tim also played a key operational role at the University of Pennsylvania’s Gene Therapy Program, where he led the Vivarium team and secured AAALAC accreditation for a new facility. His career reflects a consistent focus on advancing transformative therapies, scaling innovation, and driving value through strategic partnerships and capital markets in both the U.S. and Europe. | https://www.linkedin.com/in/tim-obara-27878912/ | https://images.squarespace-cdn.com/content/v1/67acf43fbd55ec44fa932e90/f362384e-5b4c-4c98-b279-8973ac26dec9/Jurata-Website-Headshots-TimObara-091625-v01.jpg?format=500w Sheila Ann Mikhail, JD, MBA | Co-Founder & Executive Chair | Sheila Mikhail has over 20 years of biopharmaceutical leadership experience and was previously CEO and co-founder of Asklepios BioPharmaceutical, Inc. (AskBio), a company she started in 2001 and sold to Bayer for a total value of $4 billion in October 2020. She also served as CEO and co-founder of Bamboo Therapeutics, which in 20 months raised $50 million, advanced a therapeutic for giant axonal neuropathy into the clinic, completed pre-IND studies for a Duchenne muscular dystrophy therapeutic, and built a GMP manufacturing facility. Bamboo was acquired by Pfizer in August 2016 in a deal valued at $827 million. | https://www.linkedin.com/in/sheila-ann-mikhail-1424a3/ | https://www.chicagobooth.edu/-/media/project/chicago-booth/daa/past-honorees/2022/chicago-booth-sheila-mikhail.jpg?cx=0.48&cy=0.32&cw=600&ch=478&hash=71552491D5DF6953D6E78937432F86B8 R. Jude Samulski, PhD | Co-Founder & Board Member | Dr. Jude Samulski received his PhD in medical microbiology and immunology from the University of Florida. His graduate work (1978-82) demonstrated the first use of AAV as a viral vector and culminated in the first U.S. patent involving non-AAV genes inserted into AAV. Dr. Samulski has worked with AAV for 40 years, and for 25 years, he was director of the University of North Carolina Gene Therapy Center. He was the scientific founder of Bamboo Therapeutics, Inc. and served as the Chief Scientific Officer and Executive Chairman of the company until its acquisition by Pfizer in 2016. Dr. Samulski has advanced therapeutics into human clinical trials for hemophilia, Duchenne muscular dystrophy, giant axonal neuropathy, and heart failure. He holds more than 200 patents related to AAV technology. | | https://news.unchealthcare.org/wp-content/uploads/sites/1159/2020/08/a-boy-with-muscular-dystrophy-was-headed-for-a-wheelchair-then-gene-therapy-arrived-image2.jpeg
News
2024-04-18 | Needle-free vaccines: leading innovation in drug delivery | Contract Pharma | https://www.contractpharma.com/exclusives/needle-free-vaccines-leading-innovation-in-drug-delivery/ 2024-03-26 | CastleVax and Jurata: from neighbours to partners at WVC | Vaccine Nation | https://vaccinenation.org/technology/castlevax-and-jurata-from-neighbours-to-partners-at-wvc/ 2023-12-05 | CEPI partners with biotech Jurata Thin Film to create needle-free mRNA vaccines and improve access | CEPI | https://cepi.net/cepi-partners-biotech-jurata-thin-film-create-needle-free-mrna-vaccines-and-improve-access 2023-09-19 | Jurata awarded $1 million through BLUE KNIGHT QuickFire Challenge and Project NextGen | Jurata | https://www.juratatf.com/news-media-1/blog-post-title-two-hfrmb 2023-01-19 | Chapel Hill's Jurata Thin Film aims to revolutionize drug delivery | NC Biotech Center | https://www.ncbiotech.org/news/chapel-hills-jurata-thin-film-aims-revolutionize-drug-delivery 2022-11-29 | UT Austin Seed Fund launched with first investment | UT News | https://news.utexas.edu/2022/11/29/ut-austin-seed-fund-launched-with-first-investment/ 2021-11-01 | Jurata announced as BLUE KNIGHT Resident QuickFire Challenge awardee | Jurata | https://www.juratatf.com/news-media-1/blog-post-title-three-j2db7
Profile links
https://www.linkedin.com/company/juratatf/ https://pitchbook.com/profiles/company/482162-68
Secondary sectors Vaccines, Biologics
Team size 1–10